These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38824623)

  • 21. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia.
    Lachaine J; Lapierre ME; Abdalla N; Rouleau A; Stip E
    Can J Psychiatry; 2015 Mar; 60(3 Suppl 2):S40-7. PubMed ID: 25886679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
    Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
    Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the impact of COVID-19 on medication adherence and health care utilization among individuals with psychotic disorders who are prescribed long-acting injectables (LAIs) or clozapine: A population-based study in Manitoba, Canada.
    MacMillan-Wang YW; Hensel JM; Leong C; Jayas R; Valencia E; Yorski A; Liu K
    Schizophr Res; 2024 Sep; 271():345-352. PubMed ID: 39089102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication.
    Campagna EJ; Muser E; Parks J; Morrato EH
    J Manag Care Spec Pharm; 2014 Jul; 20(7):756-66. PubMed ID: 24967528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
    Fang SC; Huang CY; Shao YJ
    J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
    [No Abstract]   [Full Text] [Related]  

  • 27. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A; Benson C; Alphs L
    J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.
    Pesa J; Liu Z; Fu AZ; Campbell AK; Grucza R
    Schizophr Res; 2023 Nov; 261():170-177. PubMed ID: 37778124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis.
    Lian L; Kim DD; Procyshyn RM; Fredrikson DH; Cázares D; Honer WG; Barr AM
    Early Interv Psychiatry; 2022 Jun; 16(6):589-599. PubMed ID: 34263540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.
    Kishimoto T; Hagi K; Nitta M; Leucht S; Olfson M; Kane JM; Correll CU
    Schizophr Bull; 2018 Apr; 44(3):603-619. PubMed ID: 29868849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
    Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
    Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study.
    Wong KO; Klarenbach SW; Martins KJB; Chue P; Dursun SM; Snaterse M; Guigue A; So H; Luu H; Vu K; Richer L
    BMC Psychiatry; 2022 Jul; 22(1):444. PubMed ID: 35780116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.
    Misawa F; Kishimoto T; Hagi K; Kane JM; Correll CU
    Schizophr Res; 2016 Oct; 176(2-3):220-230. PubMed ID: 27499361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.
    Pilon D; Joshi K; Tandon N; Lafeuille MH; Kamstra RL; Emond B; Lefebvre P
    Patient Prefer Adherence; 2017; 11():619-629. PubMed ID: 28356723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.
    Schoretsanitis G; Kane JM; Correll CU; Rubio JM
    Schizophr Bull; 2022 Mar; 48(2):296-306. PubMed ID: 34355232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.
    Verdoux H; Pambrun E; Tournier M; Bezin J; Pariente A
    Acta Psychiatr Scand; 2017 May; 135(5):429-438. PubMed ID: 28332704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: A naturalistic cohort study.
    Groenendaal E; Lynch S; Dornbush R; Klepacz L; Ferrando S
    J Psychiatr Res; 2023 Feb; 158():273-280. PubMed ID: 36623361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.